Cost-Effectiveness and Budget Impact Analysis of New Drug Therapies: A Comprehensive Study in Pharmacoeconomics

Clicks: 1
ID: 309224
2024
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #152 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This study highlights the economic viability of innovative medication therapies within healthcare systems by examining their cost-effectiveness and budget impact across neurological disorders, cancer, and cardiovascular diseases. With an incremental cost-effectiveness ratio (ICER) of $8,333 every Quality-Adjusted Life Year (QALY), Drug A has the best cost-effectiveness profile, according to the analysis, making it a desirable choice for healthcare providers. Drug B, on the other hand, has a higher ICER of $12,500 per QALY, but its substantial advantages to oncology offset its costs. In contrast, Drug C has a somewhat modest health gain and, at $15,000 per QALY, its ICER suggests that it be carefully evaluated. The budget impact analysis emphasizes the various cost ramifications of putting these cures into practice, highlighting how crucial strategic planning is to the adoption of new drugs. Additionally, sensitivity and scenario analyses show how differences in market entry tactics and medicine prices can have a big impact on budget impact and cost-effectiveness. The results support well-informed decision-making that strikes a compromise between improving patient outcomes and economic sustainability, offering legislators and healthcare professionals insightful information when implementing novel pharmacological treatments.
Reference Key
imported_1761926687_6904de1f7d0c8 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Anjali Singh
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2024
DOI
10.62896/ijpdd.1.10.3
URL
https://ijpdd.org/index.php/files/article/view/161
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.